Enhanced solubility and bioavailability of pioglitazone nanosuspension

Reema Narayan, Zenab Attari, M. Sreenivasa Reddy, K. B. Koteshwara

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Pioglitazone hydrochloride, a hypoglycemic agent, is a BCS class II drug with low solubility and thus, limited bioavailability. In the present study, nanosuspension of pioglitazone was prepared by high pressure homogenization using different stabilizers at different concentrations (0.25 to 3.0% w/v) and optimized and characterized for particle size, zeta potential, drug content, FT-IR and DSC analysis. The particle size of the optimized nanosuspension stabilized with 1% tween 80 (coded as NS17) was observed to be 433 nm and zeta potential of −36.76 mV indicated good physical stability. The nanoformulation was also found to be stable during storage of 30 days at 2–8 °C. The optimized nanosuspension, NS17 showed increased solubility, in vitro dissolution rate and improved pharmacokinetics in Wistar rats as compared to the marketed formulation.

Original languageEnglish
Pages (from-to)987-994
Number of pages8
JournalAdvanced Science Letters
Volume22
Issue number4
DOIs
Publication statusPublished - 01-04-2016

Fingerprint

pioglitazone
Solubility
Zeta potential
Particle Size
Biological Availability
bioavailability
Drugs
solubility
drug
Particle size
particle size
Pharmacokinetics
Polysorbates
Dissolution
Hypoglycemic Agents
Homogenization
Pharmaceutical Preparations
Wistar Rats
Rats
dissolution

All Science Journal Classification (ASJC) codes

  • Engineering(all)
  • Environmental Science(all)
  • Computer Science(all)
  • Energy(all)
  • Mathematics(all)
  • Health(social science)
  • Education

Cite this

@article{a4bdbf0f3db34369b666c907c4b1e890,
title = "Enhanced solubility and bioavailability of pioglitazone nanosuspension",
abstract = "Pioglitazone hydrochloride, a hypoglycemic agent, is a BCS class II drug with low solubility and thus, limited bioavailability. In the present study, nanosuspension of pioglitazone was prepared by high pressure homogenization using different stabilizers at different concentrations (0.25 to 3.0{\%} w/v) and optimized and characterized for particle size, zeta potential, drug content, FT-IR and DSC analysis. The particle size of the optimized nanosuspension stabilized with 1{\%} tween 80 (coded as NS17) was observed to be 433 nm and zeta potential of −36.76 mV indicated good physical stability. The nanoformulation was also found to be stable during storage of 30 days at 2–8 °C. The optimized nanosuspension, NS17 showed increased solubility, in vitro dissolution rate and improved pharmacokinetics in Wistar rats as compared to the marketed formulation.",
author = "Reema Narayan and Zenab Attari and {Sreenivasa Reddy}, M. and Koteshwara, {K. B.}",
year = "2016",
month = "4",
day = "1",
doi = "10.1166/asl.2016.6979",
language = "English",
volume = "22",
pages = "987--994",
journal = "Advanced Science Letters",
issn = "1936-6612",
publisher = "American Scientific Publishers",
number = "4",

}

Enhanced solubility and bioavailability of pioglitazone nanosuspension. / Narayan, Reema; Attari, Zenab; Sreenivasa Reddy, M.; Koteshwara, K. B.

In: Advanced Science Letters, Vol. 22, No. 4, 01.04.2016, p. 987-994.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Enhanced solubility and bioavailability of pioglitazone nanosuspension

AU - Narayan, Reema

AU - Attari, Zenab

AU - Sreenivasa Reddy, M.

AU - Koteshwara, K. B.

PY - 2016/4/1

Y1 - 2016/4/1

N2 - Pioglitazone hydrochloride, a hypoglycemic agent, is a BCS class II drug with low solubility and thus, limited bioavailability. In the present study, nanosuspension of pioglitazone was prepared by high pressure homogenization using different stabilizers at different concentrations (0.25 to 3.0% w/v) and optimized and characterized for particle size, zeta potential, drug content, FT-IR and DSC analysis. The particle size of the optimized nanosuspension stabilized with 1% tween 80 (coded as NS17) was observed to be 433 nm and zeta potential of −36.76 mV indicated good physical stability. The nanoformulation was also found to be stable during storage of 30 days at 2–8 °C. The optimized nanosuspension, NS17 showed increased solubility, in vitro dissolution rate and improved pharmacokinetics in Wistar rats as compared to the marketed formulation.

AB - Pioglitazone hydrochloride, a hypoglycemic agent, is a BCS class II drug with low solubility and thus, limited bioavailability. In the present study, nanosuspension of pioglitazone was prepared by high pressure homogenization using different stabilizers at different concentrations (0.25 to 3.0% w/v) and optimized and characterized for particle size, zeta potential, drug content, FT-IR and DSC analysis. The particle size of the optimized nanosuspension stabilized with 1% tween 80 (coded as NS17) was observed to be 433 nm and zeta potential of −36.76 mV indicated good physical stability. The nanoformulation was also found to be stable during storage of 30 days at 2–8 °C. The optimized nanosuspension, NS17 showed increased solubility, in vitro dissolution rate and improved pharmacokinetics in Wistar rats as compared to the marketed formulation.

UR - http://www.scopus.com/inward/record.url?scp=84985945046&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84985945046&partnerID=8YFLogxK

U2 - 10.1166/asl.2016.6979

DO - 10.1166/asl.2016.6979

M3 - Article

VL - 22

SP - 987

EP - 994

JO - Advanced Science Letters

JF - Advanced Science Letters

SN - 1936-6612

IS - 4

ER -